FDA Brief

Warning letters Drugs

FDA warning letter to

M Six Labs, Inc.

High riskIssued May 4, 2022Posted May 4, 2022Center for Drug Evaluation and Research | CDER

FDA warned M Six Labs over unapproved CBD/Delta-8 THC drugs, illegal CBD/Delta-8 foods, and animal drugs sold online.

What happened

FDA reviewed https://m6labs.com in February 2022 and found the company took orders for human and animal products represented as containing CBD or Delta-8 THC. FDA said website claims—such as cancer, anxiety, pain, seizures, and inflammation—made the human products unapproved new drugs. The letter also cites CBD and Delta-8 THC in foods and CBD products for animals.

What FDA found

  1. Human CBD and Delta-8 THC products were marketed with claims to treat or prevent disease, making them unapproved drugs.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. The human products' labeling lacked adequate directions for use, which FDA calls misbranded.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)
  3. CBD and Delta-8 THC added to food were unsafe food additives, making those foods adulterated (illegal because they contain an unsafe additive).

    FD&C Act section 402(a)(2)(C)(i), 21 U.S.C. 342(a)(2)(C)(i)
  4. CBD added to food was also a prohibited act under the FD&C Act.

    FD&C Act section 301(ll), 21 U.S.C. 331(ll)
  5. CBD products for animals were unapproved animal drugs and were unsafe and illegal under the drug law.

    FD&C Act sections 512(a) and 501(a)(5), 21 U.S.C. 360b(a) and 351(a)(5)
  6. CBD products marketed as dietary supplements did not meet the legal definition of a dietary supplement.

    FD&C Act sections 201(ff)(3)(B)(i) and (ii), 21 U.S.C. 321(ff)(3)(B)(i) and (ii)

What FDA wants

FDA asks the company to notify FDA in writing within 15 working days of steps taken to correct the violations and prevent recurrence, or to explain any delay and give a completion date.

Who should pay attention

  • retailers and distributors selling CBD or Delta-8 THC products
  • brands making CBD or Delta-8 foods, supplements, or pet products
  • contract manufacturers and labs testing cannabinoid products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk